PROCEPT BioRobotics (NASDAQ:PRCT) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its quarterly earnings data on Wednesday. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.04, Briefing.com reports. PROCEPT BioRobotics had a negative return on equity of 46.59% and a negative net margin of 77.75%. The firm had revenue of $44.50 million for the quarter, compared to analysts’ expectations of $41.58 million. During the same period last year, the business posted ($0.63) earnings per share. The firm’s revenue for the quarter was up 82.4% on a year-over-year basis. PROCEPT BioRobotics updated its FY 2024 guidance to EPS.

PROCEPT BioRobotics Trading Up 2.5 %

PRCT traded up $1.52 during trading on Thursday, reaching $62.13. The company had a trading volume of 719,693 shares, compared to its average volume of 526,924. The firm’s 50-day simple moving average is $49.69 and its 200 day simple moving average is $43.24. The company has a market cap of $3.19 billion, a price-to-earnings ratio of -27.19 and a beta of 0.95. PROCEPT BioRobotics has a 12-month low of $24.83 and a 12-month high of $63.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.77 and a current ratio of 7.63.

Insider Buying and Selling

In other PROCEPT BioRobotics news, CFO Kevin Waters sold 904 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $50.00, for a total transaction of $45,200.00. Following the completion of the sale, the chief financial officer now directly owns 33,523 shares in the company, valued at approximately $1,676,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Alaleh Nouri sold 14,694 shares of PROCEPT BioRobotics stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $49.97, for a total transaction of $734,259.18. Following the completion of the sale, the executive vice president now directly owns 47,351 shares in the company, valued at approximately $2,366,129.47. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Kevin Waters sold 904 shares of PROCEPT BioRobotics stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $50.00, for a total value of $45,200.00. Following the sale, the chief financial officer now owns 33,523 shares of the company’s stock, valued at $1,676,150. The disclosure for this sale can be found here. In the last quarter, insiders have sold 94,149 shares of company stock valued at $4,653,720. 19.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on PRCT. Wells Fargo & Company raised their price objective on PROCEPT BioRobotics from $44.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 9th. Truist Financial raised their price objective on PROCEPT BioRobotics from $63.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of “Buy” and a consensus price target of $49.50.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).